Ligand Pharmaceuticals | LGND - Operating Profit


Ligand Pharmaceuticals reported $56.62M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Agenus USD 15.05M 656K Mar/2026
Amgen USD 4.61B 777M Jun/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -141.26M 182.07M Mar/2026
Baxter International USD 276M 210M Jun/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Enviri Corporation USD -35.28M 61.58M Dec/2025
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.6B 312M Jun/2026
Glaxosmithkline GBP 2.29B 3.08M Mar/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Insmed USD -101.31M 98.97M Jun/2026
Intrexon USD -60.84M 26.62M Jun/2024
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
Ligand Pharmaceuticals USD 56.62M 3.7M Jun/2026
MacroGenics USD -33.44M 21.34M Mar/2026
Merck USD 840M 2.72B Jun/2026
Pacira USD 9.96M 5.33M Jun/2026
Pfizer USD 667M 4.32B Jun/2026
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Veracyte USD 23.96M 4.88M Jun/2026